IGF2BP3 promotes the stability and translation of epidermal growth factor receptor (EGFR) mRNA and further activates the EGFR pathway by cooperating with METTL14 to increase cetuximab resistance in CRC cells (Chen L. J. et al., 2023). This evidence concerns the gene IGF2BP3 and colorectal carcinoma.